Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Follow-up after post-exposure prophylaxis before and during the COVID-19 pandemic in Brazil

View ORCID ProfileElaine Monteiro Matsuda, View ORCID ProfileIvana Barros de Campos, View ORCID ProfileLuís Fernando de Macedo Brígido
doi: https://doi.org/10.1101/2024.03.07.24303803
Elaine Monteiro Matsuda
1Secretaria da Saúde de Santo André. Santo André, São Paulo, Brasil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Elaine Monteiro Matsuda
  • For correspondence: elainemmatsuda{at}gmail.com
Ivana Barros de Campos
2Instituto Adolfo Lutz. Centro Regional de Santo André. Santo André, São Paulo, Brasil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ivana Barros de Campos
Luís Fernando de Macedo Brígido
3Instituto Adolfo Lutz. Centro de Virologia. São Paulo, São Paulo, Brasil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Luís Fernando de Macedo Brígido
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Although post-exposure prophylaxis (PEP) is a powerful tool to abort HIV infection within 72 hours of exposure, blocking the establishment of chronic infection, follow-up metrics of this intervention are scarce. As antiretroviral use delays diagnosis biomarkers, the moment to perform serological evaluations must be considered this to avoid missed diagnosis opportunities. We assessed the return adherence after PEP dispensation in service in the Sao Paulo metropolitan area and reviewed the literature, both showing limited adherence to current protocols and leading to difficulties in diagnosing early HIV infection. The current proposed date for the first return after PEP is associated with low adherence and may have limited capability to detect antibodies if the infection is present. Guidelines should allow a longer time after PEP discontinuation along with message reminders to encourage adherence and avoid false negative results that can be detrimental both to the patient and to the community.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq - 442776/2019-5). Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (Fapesp - 2018/14384-9).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the research ethics committee of the Abc Faculty of Medicine under number CAAE21164819.7.0000.0082.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • elainemmatsuda{at}gmail.com

  • ivanacamp{at}gmail.com

  • lubrigido{at}gmail.com

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted March 08, 2024.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Follow-up after post-exposure prophylaxis before and during the COVID-19 pandemic in Brazil
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Follow-up after post-exposure prophylaxis before and during the COVID-19 pandemic in Brazil
Elaine Monteiro Matsuda, Ivana Barros de Campos, Luís Fernando de Macedo Brígido
medRxiv 2024.03.07.24303803; doi: https://doi.org/10.1101/2024.03.07.24303803
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Follow-up after post-exposure prophylaxis before and during the COVID-19 pandemic in Brazil
Elaine Monteiro Matsuda, Ivana Barros de Campos, Luís Fernando de Macedo Brígido
medRxiv 2024.03.07.24303803; doi: https://doi.org/10.1101/2024.03.07.24303803

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • HIV/AIDS
Subject Areas
All Articles
  • Addiction Medicine (349)
  • Allergy and Immunology (668)
  • Allergy and Immunology (668)
  • Anesthesia (181)
  • Cardiovascular Medicine (2648)
  • Dentistry and Oral Medicine (316)
  • Dermatology (223)
  • Emergency Medicine (399)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (942)
  • Epidemiology (12228)
  • Forensic Medicine (10)
  • Gastroenterology (759)
  • Genetic and Genomic Medicine (4103)
  • Geriatric Medicine (387)
  • Health Economics (680)
  • Health Informatics (2657)
  • Health Policy (1005)
  • Health Systems and Quality Improvement (985)
  • Hematology (363)
  • HIV/AIDS (851)
  • Infectious Diseases (except HIV/AIDS) (13695)
  • Intensive Care and Critical Care Medicine (797)
  • Medical Education (399)
  • Medical Ethics (109)
  • Nephrology (436)
  • Neurology (3882)
  • Nursing (209)
  • Nutrition (577)
  • Obstetrics and Gynecology (739)
  • Occupational and Environmental Health (695)
  • Oncology (2030)
  • Ophthalmology (585)
  • Orthopedics (240)
  • Otolaryngology (306)
  • Pain Medicine (250)
  • Palliative Medicine (75)
  • Pathology (473)
  • Pediatrics (1115)
  • Pharmacology and Therapeutics (466)
  • Primary Care Research (452)
  • Psychiatry and Clinical Psychology (3432)
  • Public and Global Health (6527)
  • Radiology and Imaging (1403)
  • Rehabilitation Medicine and Physical Therapy (814)
  • Respiratory Medicine (871)
  • Rheumatology (409)
  • Sexual and Reproductive Health (410)
  • Sports Medicine (342)
  • Surgery (448)
  • Toxicology (53)
  • Transplantation (185)
  • Urology (165)